Popular Posts

Friday, 13 April 2018

Walk in interview@Lupin for multiple positions on 19 April

Company: Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for Cefuroxime Axetil Tablets. Since then we have received more than 75 FDA
approvals and have become one of the fastest growing pharmaceutical companies in the US. Our consistent track record of growth is a result of a valuable pipeline, solid customer relationships, and flawless execution.
We are vertically integrated, from process development of the API to the submission of dossiers for finished dosages. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive prices.
Our integrated manufacturing capability provides a portfolio of the highest quality generic products.
Expanding the product portfolio, Lupin Pharmaceuticals, Inc. is geared to file 20 or more ANDA's per year in some of the following areas:
Click here for interview details